PER-003-04已完成未知
RANDOMIZED STUDY OPEN PHASE 3, OF TEMOZOLOMIDE ADDED TO TOTAL RADIATION THERAPY OF THE BRAIN COMPARED WITH TOTAL RADIATION THERAPY OF THE SINGLE CEREBRUM FOR THE TREATMENT OF CEREBRAL METASTASES FROM NON-SMALL CELL LUNG CANCER
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age greater than or equal to 18
- •Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)
- •At least one brain metastasis diagnosed within 30 days of randomization
- •Brain metastases must not have been previously treated with WBRT or radiosurgery
- •No more than 2 sites of extracranial metastases
- •May have received prior radiation therapy to the primary tumor and/or systemic metastatic sites
- •Meets protocol requirements for specified laboratory values.
- •Written informed consent and cooperation of patient
- •Appropriate use of effective contraception if of childbearing potential.
- •Karnofsky Performance Status KPS greater than 70
- •Score less than 2 on all criteria of the Comprehensive Neurological Outcome Scale (CNOS)
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATIONVERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSElderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are not deemed suitable by their treating physician to receive the standard radiotherapy regimen (60 Gy / 30 fractions over 6 weeks) in combination with temozolomide.MedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2008-001949-26-FREORTC European Organisation for Research and Treatment of Cancer560
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS - NDElderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are not deemed suitable by their treating physician to receive the standard radiotherapy regimen (60 Gy / 30 fractions over 6 weeks) in combination with temozolomide.MedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2008-001949-26-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER562
已完成
3 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSGlioblastomaJPRN-UMIN000002434ational Cancer Institute of Canada560
已完成
3 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSgrade IV brain tumor10029211glioblastomaNL-OMON39213European Organisation for Research in Treatment of Cancer (EORTC)45
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATIONVERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSEUCTR2008-001949-26-BEEORTC European Organisation for Research and Treatment of Cancer560